Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2015 6,97 M
EBIT 2015 -16,3 M
Net income 2015 -17,4 M
Debt 2015 1,45 M
Yield 2015 -
Sales 2016 18,4 M
EBIT 2016 -11,1 M
Net income 2016 -12,4 M
Finance 2016 0,70 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 29,6x
EV / Sales 2016 11,1x
Capitalization 205 M
More Financials
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Sector
Pharmaceuticals
Calendar
07/30Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
07/01 ONXEO : Validive® at the MASCC/ISOO International Symposium:
07/01 ONXEO : Validive® at the MASCC/ISOO International Symposium: Oral presentation o..
06/28 ONXEO : BELIEF Study Published in the Journal of Clinical Oncology (JCO)
06/28 ONXEO : Updates on Publication of Beleodaq (belinostat) Pivotal BELIEF Study Res..
06/27 ONXEO : Secures US Patent Protecting Validive Until 2029
06/26 ONXEO : Beleodaq® (belinostat) Pivotal BELIEF Study Results Published in the Jou..
06/26 ONXEO : Reports Publication of Beleodaq (belinostat) Pivotal BELIEF Study Result..
06/26 ONXEO : Study Pivotal BELIEF Published in the Journal of Clinical Oncology (JCO)
More news
Sector news : Pharmaceuticals - NEC
04:31p PFIZER : Announces FDA Acceptance for Review of New Drug Application for A Once-..
02:55pDJVERTEX PHARMACEUTICALS : $259,000 Cystic Fibrosis Drug Approved
02:45p JOHNSON & JOHNSON : Investigational HIV Vaccine Regimen Shows Encouraging Result..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions